Viropro Inc. and the Biotechnology Research Institute of the National Research Council Canada (NRC-BRI) have signed an agreement in principle for the development and updating of production procedures for biopharmaceutical products, other biological materials as well as projects for business development.

According to a company release, the aim of this agreement is to create, within different research projects, a synergy of expertise and of technology transfers ranging from the early stage of preculture to the fine-tuning of production and purification procedures. The marketing of recombinant proteins and a new vaccination platform are at the core of the business strategy behind this alliance.

"We are very happy about this collaboration with the NRC-BRI as part of our business development strategy for biopharmaceutical products. We will give precedence to co-development agreements for procedures used in the manufacturing of biopharmaceutical products with the intention of technological transfers with our business partners in the areas targeted by Viropro," said Dr. Jean-Marie Dupuy, chief executive officer of Viropro.

"We are very pleased with this agreement with Viropro because of its dynamic and proactive approach and we feel confident that we will succeed in finding new technological manufacturing approaches," said Dr. Michel Desrochers, general manager of the NRC-BRI.

Recognised worldwide for its innovation and research work, the National Research Council Canada (NRC) is a leader in the development of an innovative economy centred on knowledge in Canada through science and technology.

Viropro, Inc is rapidly establishing a growth portfolio in the life sciences market through strategic alliances and revenue-producing acquisitions.